Upstream eventIncrease, Chromosomal aberrations
Increase, lung cancer
Key Event Relationship Overview
AOPs Referencing Relationship
|AOP Name||Adjacency||Weight of Evidence||Quantitative Understanding|
|Direct deposition of ionizing energy onto DNA leading to lung cancer||non-adjacent||Moderate||Moderate|
Life Stage Applicability
|All life stages||High|
Key Event Relationship Description
Chromosomal aberrations (CAs) are described as irregularities in chromosome structure due to segments of the chromosome that have been lost, gained, or rearranged. This can lead to two categories of chromosomal exchanges: balanced, which do not impact the overall frame of chromosome structure, and unbalanced, which refers to CAs that do alter the frame of chromosome structure (Genetic Alliance 2010) . Specific categories of CAs include chromosome-type aberrations (CSAs) such as chromosome-type breaks, ring chromosomes, marker chromosomes, and dicentric aberrations; chromatid-type aberrations (CTAs) such as chromatid breaks and chromatid exchanges (Hagmar et al. 2004; Bonassi et al. 2008); micronuclei (MN); nucleoplasmic bridges (NPBs); and copy number variants (CNVs). When CAs affect genes related to tumourigenesis or their regulatory regions (Shlien and Malkin 2009; Liu et al. 2013), this may lead to an abnormal accumulation of malignant cells and ultimately may result in cancer. Lung cancer in particular may occur if these tumourigenesis-related CAs (which are more often unbalanced than balanced in lung cancer (Mitelman et al. 1997) occur in cells of the lung.
Evidence Supporting this KER
The biological rationale linking CAs with lung cancer is strongly supported. There are many epidemiological studies that provide evidence of a link between increasing CAs and cancer incidence. Several published reports spanning over 22,000 study subjects across multiple European countries have examined the association between the presence of CAs in cultured blood lymphocytes and the incidence of cancer. In every cohort examined, the presence of CAs was predictive of cancer risk (Bonassi et al. 2000; Hagmar et al. 2004; Norppa et al. 2006; Boffetta et al. 2007; Bonassi et al. 2008). Although CSAs and CTAs both had predictive value, CSAs were considered to be slightly more indicative of cancer risk (Norppa et al. 2006). Similarly, studies examining chromosomes in lymphocytes from lung cancer patients found significant increases in CTAs, CSAs, and overall CAs relative to lymphocytes from healthy controls. Furthermore, the CAs were shown to be significant predictors of lung cancer risk (Vodenkova et al. 2015). Analysis of MN and NPB levels within binucleated cells also found that these CAs were significantly increased in lung cancer patients relative to healthy controls (Lloyd et al. 2013; El-zein et al. 2014; El-zein et al. 2017), with very similar results for geographically-separated test and validation cohorts (El-zein et al. 2014).
Exposure to radiation has also been epidemiologically linked to the relationship between CAs and cancer. Studies of radon-exposed uranium miners have revealed evidence of an association between exposure to radon gas and an increased incidence of lung cancer (Roscoe et al. 1989; Tirmarchel et al. 1993; Smerhovsky et al. 2001; Smerhovsky et al. 2002; Vacquier et al. 2008; Walsh et al. 2010). Analysis of CAs in the blood lymphocytes of miners from the Czech Republic found that miners with higher levels of CAs had a significantly elevated risk of cancer (Smerhovsky et al. 2001; Smerhovsky et al. 2002). The results from these studies were likely not due to smoking status of the miners, as a study examining a cohort of 516 white, never-smoker American uranium miners found that the mortality rates from lung cancer were higher in the miners than in the general non-smoking population (Roscoe et al. 1989).
Beyond epidemiology, there are also many genetic and molecular studies that provide strong evidence of a relationship between CAs and cancer. A subset of these studies have investigated copy number variants (CNVs). Examination of CNVs and known cancer genes in a large population revealed that CNVs often overlap with cancer genes and thus have the potential to amplify carcinogenesis (Shlien and Malkin 2009; Ohshima et al. 2017)Moreover, using only CNV genetic information from a database, Zhang et al (2016) were able to categorize 3,480 samples into their respective cancer type based solely on the CNVs of the samples. This was accomplished by developing a panel of 19 discriminating genes that could predict cancer type with a high level of accuracy using only the CNV number. Interestingly, many of these discriminating genes have known associations with cancer or processes known to be important in cancer development (Zhang et al. 2016). Furthermore, cancer-prone individuals tend to have more CNV instability, which has been attributed to inherently less efficient DNA repair mechanisms (Shlien and Malkin 2009). In their 2013 review, Liu et al provided lists of cancer-related genes typically amplified by CNVs (ERBB2, EGFR, MYC, PIK3CA, IGF1R, FGFR1/2, KRAS, CDK4, CCDN1, MDM2, MET, and CDK6) and deleted by CNVs (RB1, PTEN, CDKN2A/B, ARID1A, MAPSK4, NF1, SMAD4, BRCA1/2, MSH2/6, DCC, and CDH1). There is also evidence associating CNVs to lung cancer specifically. Analysis of primary NSCLC samples revealed 27 chromosomal regions where CNVs were present in at least one third of the samples (Wrage et al. 2009). Furthermore, medically-relevant CNVs were found in 60% of lung cancer patients, encompassing genes such as TP53, BAP1, STK11, BRCA2, CDKN2A, and RB1 (Mukherjee et al. 2016).
Likewise, lung cancer-specific studies have been performed to identify chromosomes most often affected by CNV gains and losses. Analysis of DNA from primary human lung tumours and early-passage primary cell lines established from human tumours revealed that gains were most frequently found at chromosomes 3q, 5p, 7p, and 8q, while losses were most frequent at chromosome 3p (Balsara et al. 1997). Separation of CNV analyses into squamous cell carcinoma and lung adenocarcinoma groups demonstrated differences between the two lung cancers (Petersen et al. 1997; Bjorkqvist et al. 1998; Feder et al. 1998; Massion et al. 2002). In general, CNV changes were present in 84% of squamous cell carcinoma samples, but only in 68% of adenocarcinomas (Bjorkqvist et al. 1998). In squamous cell carcinoma, the most frequent gain was found at chromosome 3q (Bjorkqvist et al. 1998), specifically at 3q26 (Massion et al. 2002); other common CNV gains were found at chromosomes 8q, 5p and 7p (Bjorkqvist et al. 1998). Losses in 3p were also more common in squamous cell carcinoma than adenocarcinoma (Feder et al. 1998). In adenocarcinoma, the most common documented CNV was a gain at chromosome 7p (Feder et al. 1998). Gains in squamous cell carcinoma were often found in genes GLUT2, THRB, PIK3CA and BCL6, and losses in FHIT, EG9F2 and CACNAID. Interestingly, CNV gains affecting PIK3CA were correlated with increased activity of PKB in squamous cell carcinoma (Massion et al. 2002). A review by Knuutila et al (1999) summarizes DNA copy number losses found in 73 human tumour types, with results separated by chromosome number.
Loss of heterozygosity is also a common occurrence in cancer. Preneoplastic lesions from seven NSCLC tumours were histologically categorized and genetically analyzed. Consistent with above studies that revealed CNV losses at chromosome 3p, loss of heterozygosity was also common at the 3p locus. Percentages of 3p loss of heterozygosity increased from hyperplastic lesions (76%) to dysplastic lesions (86%) to carcinoma in situ (100%). Overall, cumulative loss of heterozygosity was nearly doubled in carcinoma in situ and invasive carcinoma lesions relative to preneoplastic hyperplasia and dysplasia lesions (Hung et al. 1995).
Other studies have revealed a link between gene rearrangements and cancer. Truncated tumour suppressor genes TP53, BRCA1 and BRAC2 have been reported in prostate cancer (Mao et al. 2011). In lung cancer, the gene ALK has been observed to undergo rearrangements, often in the form of gene fusions with EML4 (Sanders and Albitar 2010; Sasaki et al. 2010). These ALK rearrangements often result in increased activity of ALK, higher activation of PI3K-AKT pathways, and ultimately an increased risk of tumourigenesis (Sanders and Albitar 2010). Another common example of a gene fusion is the Philadelphia chromosome, which is formed by a translocation between chromosome 9 and 22 and results in the fusion of BCR and ABL genes. The resulting BCR/ABL gene fusion product was found to be the cause of chronic myelogenous leukemia (reviewed by (Trask 2002). This fusion may be induced by stressors such as ionizing radiation; exposure of human leukemic promyelocytic cells (HL-60) to 5 Gy of gamma-ray radiation resulted in homologous BCR and ABL genes in closer proximity to each other and to the centre of the nucleus (Bartova et al. 2000).
Several rearrangements have also been significantly associated with lung cancer. A balanced translocation at chromosome 19 that results in overexpression of Notch3 in lung epithelial cells has been identified in a number of NSCLC lung cancer cell lines and tumours. This is significant, as Notch3 is not normally expressed in the cells of the lungs (Dang et al. 2000). In fact, transgenic mice engineered to overexpress Notch3 in the lung epithelium died at birth. Analysis of these embryos at embryonic day 18.5 revealed tissue abnormalities in locations where Notch3 mRNA was found, which suggests that overexpression of Notch3 in the lungs may play a role in lung tumourigenesis (Dang et al. 2003). Significant associations have been found between rearrangements in chromosome Xp and higher NSCLC tumour stage, as well as rearrangements in 17p and lower NSCLC tumour stage; 3p and 6q rearrangements were linked with better NSCLC survival (Feder et al. 1998).
CAs that affect pathways controlling cellular growth and apoptosis may promote the development of cancer. In some cases, CAs may alter the activity of proto-oncogenes or tumour suppressor genes (Mitelman et al. 1997; Albertson et al. 2003). Proto-oncogene regulation may be modified such that its gene product is overexpressed; alternatively, the product of the proto-oncogene itself may be affected, producing an abnormally-functioning protein. CAs that affect tumour suppressor genes may inactivate its expression; deletion of the chromosome housing the tumour suppressor gene(s) or unbalanced structural rearrangements may also prevent the expression of tumour suppressor genes (Mitelman et al. 1997). If these alterations enhance cell growth and/or inhibit apoptosis, the cell may become excessively proliferative and unresponsive to external environmental signals (Albertson et al. 2003). There are several pathways that could conceivably be pushed towards malignant transformation by the formation of CAs, including signalling pathways AKT-PI3K-mTOR and RAS-REF-MEK. If a CA occurs within gene(s) related to either of these pathways such that the activity is augmented, this may contribute to the development of a tumour (Sanders and Albitar 2010).
Other factors that may also contribute to increasing the CAs in a tumour include aberrant centromeres and telomerase deficiencies. In some cases, centromeres may become abnormally large due to aberrant amplification. These large centromeres may no longer separate the chromosomes appropriately during cell division, increasing the CA burden in the resulting daughter cells. In telomerase-deficient tumour cells that are proliferating but not being monitored closely, the telomeres may become abnormally short. This becomes an issue for cells that continue dividing because the chromosomes may become damaged during cell division, resulting in chromosomal fusions and breakages. Ultimately, this would also increase the CAs in the daughter cells (Albertson et al. 2003).
Ionizing radiation may also play a role in carcinogenesis. A series of studies focussed on irradiating human papillomavirus (HPV18)-immortalized human bronchial epithelial cells and transplanting the cells into nude mice. The transplantation of these irradiated cells resulted in tumour induction, an effect that was not found when unirradiated cells were transplanted into the mice (Hei et al. 1994). From these tumours, 6 different tumour cell lines were established and analyzed for cytogenetics. All of the lines were found to have CAs, and all harboured losses in genetic information (Weaver et al. 1997). Establishment of further tumour cell lines and their subsequent genetic analysis confirmed that there were CAs, especially in the form of deletions, that were common among the different tumour cell lines (Weaver et al. 2000).
Whether the CA is spontaneous or inherited may also be an important factor in the development of cancer. Non-clonal CAs, which are acquired spontaneously, promote genetic instability and are thought to confer a growth advantage. Ionizing radiation and carcinogens are two stressors that are thought to push the cell towards production of non-clonal CAs, which dominate during the pre-crisis stage of tumour development. After the tumour cells have passed the crisis stage and become immortal, clonal CAs (which are stable, inherited and recurrent in the cell population) dominate the CA landscape of the tumour. Clonal CAs are thought to confer a survival advantage to the cells. Overall, it is suggested that the shifting of equilibrium between non-clonal and clonal CAs is key in the initiation and progression of cancers (Heng, Stevens, et al. 2006; Heng, Bremer, et al. 2006). Interestingly, non-clonal CAs are affected by genotype. In both mouse embryonic stem cells and cultured lymphocytes that were lacking ATM, the spontaneous frequency of non-clonal CAs were significantly increased relative to wild-type cells; the same pattern was also observed in p53-/- cells from a human lung cancer cell line and an ovarian carcinoma cell line (Heng, Stevens, et al. 2006).
There is moderate empirical evidence supporting the relationship between the incidence of CAs and the development of lung cancer in the presence of ionizing radiation. The evidence presented below is summarized in table 11, here (click link). Radon gas exposure in particular is linked to this process, and there are several published reviews that provide evidence for associations between radon exposure and the appearance of CAs, and radon exposure and the incidence of lung cancer (Jostes 1996; Al-Zoughool and Krewski 2009; Robertson et al. 2013). Genetic abnormalities found in lung cancer that result in genomic instability are also discussed by Massion (2003). Overall, however, there is little empirical evidence available supporting a dose and incidence concordance, some empirical evidence supporting a temporal concordance, and little empirical evidence supporting essentiality for this KER.
Dose and Incidence Concordance
There is a lack of empirical evidence to show dose and incidence concordance between CAs and lung cancer, particularly in the field of ionizing radiation. As described above, numerous studies are available that provide strong evidence linking CAs to cancer incidence, radiation exposure to CA frequency, and radiation exposure to cancer incidence. However, there is a lack of studies that assess whether increasing doses of a stressor, such as ionizing radiation, translate into dose-dependent changes in CA frequencies and dose-dependent changes in cancer incidences. Attempts were thus made to locate studies using similar radiological and biological conditions that assessed CA frequency and/or cancer incidence in response to a stressor.
Evidence from several epidemiological studies suggests a dose/incidence concordance between the appearance of CAs and lung cancer incidence upon radiation exposure. In humans, this association has been studied in different cohorts of uranium miners that were occupationally exposed to radon in the 1900s. (It is important to note that radon exposure was reported as working level months (WLM). One WLM is calculated based on 170 hours of exposure to one working level (WL), where 1 WL refers to the equivalent of 1.3 x105 MeV of alpha particle energy in 1 L of air. Damage from 1 WLM is thought to be equivalent to 0.8 - 10.0 mGy (Jostes 1996); this corresponds to 100 - 1250 WLM/Gy.) One of these uranium miner studies examined the relationship between radon exposure, CAs and lung cancer. In a cohort consisting of 225 radon-exposed miners from the Czech Republic, 1,323 cytogenetic assays were performed and 20 cases of respiratory and intrathoracic organ cancers were recorded. Over the course of their employment, mine workers were estimated to be exposed to 1.7 - 662.3 WLM, with approximately one-third of miners exposed to doses above 80 WLM. There were significant associations found between the radiation dose and both the percentage of aberrant cells and frequency of chromatid breaks. Furthermore, an increased risk of lung cancer was revealed in subjects with high frequencies of CAs. Radon exposure was also found to be a significant predictor of lung cancer incidence (Smerhovsky et al. 2002). In addition, other studies examining uranium miners from different countries found a significant association between the cumulative radon exposure and the risk of lung cancer (Tirmarchel et al. 1993; Vacquier et al. 2008; Walsh et al. 2010).
Evidence from in vivo and in vitro studies has also revealed similar associations. In a study examining mouse bronchial epithelial cells for CAs, 1 Gy of X-ray radiation was found to induce a significant increase in the percentage of binucleated cells with MN relative to unirradiated controls (Werner et al. 2017). Similarly, rats irradiated with 1 Gy of thoracic X-rays between 1 and 15 weeks of age were found to develop significantly more lung tumours than unirradiated controls (Yamada et al. 2017). Several studies using lung and non-lung cell lines have also shown that a dose-dependent increase in CAs occurs with increasing radiation doses of X-rays between 0 and 5 Gy (Yamada et al. 2002) and alpha particles between 0 and 2.23 Gy (Nagasawa et al. 1990; Deshpande et al. 1996; Yamada et al. 2002; Stevens et al. 2014). Coinciding with these results, oncogenic transformations were found in non-lung cell lines irradiated with similar radiation doses; specifically, dose-dependent increases in oncogenic transformations were evident between 0 and 2.5 Gy of both X-rays (Robertson et al. 1983) and alpha particles (Robertson et al. 1983; Miller et al. 1996). Relative to X-ray exposed cells, those exposed to alpha particles had more MN accumulated per Gy (Yamada et al. 2002) and more oncogenic transformations (Robertson et al. 1983). Likewise, in vivo studies demonstrated a dose-dependent increase in MN in lung fibroblasts isolated from Wistar rats exposed to 0 - 11.3 Gy of gamma-ray radiation (Brooks et al. 1995), Wistar rats exposed to 0 - 323 WLM of radon, and Syrian hamsters exposed to 0 - 278 WLM of radon (Khan et al. 1995). When the incidence of lung carcinomas was examined in Sprague-Dawley rats exposed to radon and radon progeny at exposure levels similar to uranium miners, there was a dose-dependent increase in lung carcinomas between 25 and 3000 WLM (Monchaux et al. 1994).
In further support of this dose-dependency between CAs and lung cancer, analyses of lung tissue with varying levels of tumourigenesis exhibited corresponding accumulations of CAs. In a KrasLA2 mouse model of lung cancer, tumours collected when the mice were 6 months of age were categorized according to size. Genomic instability in the form of CNVs significantly increased with increasing tumour size; this was especially true in chromosome 6, which houses the KRAS gene (To et al. 2011). Similarly, analysis of human lung tissue categorized according to the level of damage (normal epithelium, hyperplasia, metaplasia, dysplasia, carcinoma in situ or invasive carcinoma) found that the loss of heterozygosity was increased with higher levels of tissue damage (Thibervile et al. 1995; Wistuba et al. 1999). These findings were especially pronounced in the chromosome 3p region (Wistuba et al. 1999), specifically at 3p21-22 (Thibervile et al. 1995). Interestingly, a review by Zabarovsky (2002) suggests that there may be multiple tumour suppressor genes at chromosome 3p, which are thought to play an important role in carcinogenesis (Zabarovsky et al. 2002). Loss of heterozygosity was also found commonly at 9p21-22 and 5q21 (Thibervile et al. 1995).
There is some empirical evidence of temporal concordance between CA frequency and lung cancer incidence after exposure to ionizing radiation. With respect to the time of irradiation, CAs have been shown to occur prior to lung tumourigenesis. Results from a number of different studies found that an increased CA burden was evident within hours or days of irradiation (Nagasawa et al. 1990; Khan et al. 1995; Deshpande et al. 1996; Yamada et al. 2002; Stevens et al. 2014; Werner et al. 2017). The development of cancer, however, was a longer process. In vitro oncogenic transformations were documented weeks after irradiation (Robertson et al. 1983; Miller et al. 1996), while in vivo lung tumours were not detected until months or years after the radiation exposure (Tirmarchel et al. 1993; Yamada et al. 2017). In terms of examining increased CAs and cancer incidence directly, injection of a CA-carrying agent into mice was shown to induce cancer within 21 - 31 days of the injection (Pear et al. 1998; Kuramochi et al. 2001).
There are few studies available that demonstrate the essentiality of CAs for the induction of lung cancer. However, two agonist-type studies were found that supported the relationship between CAs and cancer, though they were not specific to the lung. In the first study, addition of a known pulmonary carcinogen to cultures of peripheral blood lymphocytes from both lung cancer patients and healthy controls resulted in significantly increased MN, NPBs and nuclear buds relative to the respective untreated cultures (Lloyd et al. 2013). The second study demonstrated a clear relationship between the BCR/ABL translocation and chronic myelogenous leukemia. In this study, BALB/c mice that were lethally irradiated received a bone marrow transplant containing retroviruses carrying the BCR/ABL translocation. Within 21 - 31 days of the transplant, all of the infected mice were found to have a disease equivalent to the human chronic myelogenous leukemia (Pear et al. 1998).
A further study manipulated TSCL1 dynamics in a xenograft mouse model. The human lung cancer cell line, A549, harbours a loss of heterozygosity at chromosome 11, which results in highly reduced levels of TSCL1. Upon injection of these cells into BALB/c mice, tumours were detectable at the injection sites by 3 weeks post-injection. In an effort to correct this defect, mini genes were engineered to carry a full-length TSCL1 gene and transfected into A549 cells which were then injected into mice. Although tumours still developed, they were fewer in number and slower growing (Kuramochi et al. 2001). Thus correction of one CA may have a measurable effect on cancer progression.
Uncertainties and Inconsistencies
Uncertainties and inconsistencies in this KER are as follows:
- CNVs are often difficult to detect in cancer cells, even with current advances in next generation sequencing. This is due to the sheer number of CNVs that could possibly be present within one tumour; the unknown ratio of cancer cells and healthy cells within a tumour sample; the unknown ploidy of tumours; and the possible presence of multiple clones in one tumour, including possible low-number subclones that may be difficult to detect (Liu et al. 2013).
- In some studies, smoking does not affect the CA-cancer relationship (Bonassi et al. 2000; Bonassi et al. 2008; El-zein et al. 2014; Vodenkova et al. 2015; El-zein et al. 2017), but it does have a significant effect in other studies (Paik et al. 2012; Lloyd et al. 2013; Minina et al. 2017).
- In a study examining MN in lung fibroblasts isolated from Wistar rats and Syrian hamsters exposed to radon, Syrian hamsters were found to have a significantly increased rate of MN per 1000 bincleated cells per Gy relative to rats. According to the literature however, Wistar rats have a higher documented sensitivity to radon-induced lung cancer than Syrian hamsters (Khan et al. 1995).
Quantitative Understanding of the Linkage
In terms of quantitatively linking the frequency of CAs with the incidence of cancer in order to form predictions, there are few studies that directly link these two events. Estimates suggest that the accumulation of 10 - 20 genetic abnormalities is required for detectable lung cancer (Danesi et al. 2003). Along a similar line of reasoning, normal cells that have been converted to tumourigenesis are thought to harbour an average loss of heterozygosity of at least 25 - 30%; it is common, however, for there to be allele losses of greater than 75% in tumour cells (Vogelstein and Kinzler 2004). Although our current overall quantitative understanding of this KER hints that it may be possible to predict CAs and lung cancer risk for known radiation exposures, more research is required to further confirm and refine the direct quantitative understanding between a radiation-based stressor, CA rates, and cancer incidence.
Below are two tables that provide examples of the quantitative understanding that currently exists between CA frequency and lung cancer, often described in terms of a radiation stressor. The first highlights predictions of CA frequency rates, while the second provides examples that highlight cancer predictions.
|Brooks, 1995||Irradiating lung fibroblasts from wistar rats in the dose (D) range 0 - 11.3 Gy resulted in a postive increase in estimated CA rate (y) (of the form y = a + bD): 4 hours (a,b := 0.02 ± 0.03, (2.38 ± 0.44)x10-2 ), 67 hours (a,b:= 0.01 ± 0.06, (1.01 ± 0.10)x10-2 ).|
|Khan, 1995||Lung fibroblasts from Wistar rats and Syrian hamsters were arradiated with Radon with equivalent doses (D) of 0-323 WLM (Wistar) and 0-278 WLM (Syrian). The estimated CA response (y) (of the form y = a + bD) were found to be: Wistar (a,b := 15.5 ± 14.4, 0.53 ± 0.06), Syrian (a,b := 38.3 ± 15.1, 0.80 ± 0.08).|
|Girard et al., 2000||NSCLC and SCLC cell lines undergo allelic loss: NSCLC - 22 ± 8 loci, SCLC - 17 ± 4.|
|Yamada, 2002||Rat alveolar epithelial cell line irradiated with X-rays or alpha particles in dose ranges 0 - 5 Gy (X-rays) and 0 - 2 Gy (alpha particles). Observation of 6.7 % increase in MN / Gy (X-rays) and 28.5 % in MN / Gy (alpha particles).|
|Stevens, 2014||V79-4 cells irradiated to alpha particles in the dose (D) range 0-2.23 Gy resulted in positive CA rate (y) (of the form y = a + bD) were found to be: Acute/High dose rate (a,b := 0.633 ± 0.2, 0.0208 ± 0.0068), Syrian (a,b := 0.523 ± 0.18, 0.0103 ± 0.0051).|
|Timarche, 1993||Study of French Uranium miners exposed to Radon in the dose (D) range of 0 - 300 WLM resulted in a calculated lung cancer risk (y) (of the form y = a + bD) based on a 0.6% per exposure to 1 WLM: (a,b) := 1.68, 0.0058.|
|Walsh, 2010||Study of German of miners exposed to Radon in the dose (D) range of 0 - 1500 WLM resulted in a calculated lung cancer risk of 1.1% per WLM (radon exposure rate: 2.7 WL).|
|Miller, 1995||C3H10T1/2 cells exposed to alpha particles with a dose of 0 - 1 Gy. Resulted in a calculated cancer risk of 22.7 ± 2.0 transformants per 104 surviving cells per Gy.|
There is evidence of a response-response relationship between radiation exposure and CAs in cells of the lung, and between radiation exposure and the risk of lung cancer in radon-exposed miners. In two different studies using lung fibroblasts isolated from irradiated rodents, there was a positive, linear, dose-dependent relationship found between the radiation dose and the number of MN (Brooks et al. 1995; Khan et al. 1995). A number of in vitro studies also confirmed the presence of a positive, linear dose-dependent relationship between the number of radiation-induced CAs and the radiation dose (Nagasawa et al. 1990; Yamada et al. 2002; Stevens et al. 2014). In studies examining mortality from lung cancer in radon-exposed uranium miners from France and Germany, there was a positive linear relationship between the radon exposure and risk of lung cancer mortality (Tirmarchel et al. 1993; Walsh et al. 2010). This relationship was found to be exponentially modified by the age at median exposure, the time since median exposure, and the radon exposure rate (Walsh et al. 2010). Furthermore, oncogenic transformations in C3H10T1/2 cells irradiated with alpha particles were found to increase in a positive, linear dose-dependent fashion (Miller et al. 1996).
There is evidence suggesting that time-related predictions can be made for CA incidence and the development of lung cancer after exposure to ionizing radiation. CAs have been demonstrated to occur within hours of irradiation and persist for days afterwards. In mouse bronchial epithelial cells, 1 Gy of X-ray radiation induced a significant increase in the percentage of binucleated cells with MN by 24 hours post-irradiation. These levels remained significantly elevated at 48 hours and 72 hours post-irradiation, though there was a time-dependent decrease in the percentage of cells with CAs. By 7 days post-irradiation, these levels were no longer significantly different from controls (Werner et al. 2017). In a similar study, lung fibroblasts were isolated and cultured from Wistar rats, Syrian hamsters and Chinese hamsters after exposure to 323, 278 and 496 WLM of radon, respectively, at 0.2, 15, and 30 days post-exposure. In all species, MN levels were highest at 0.2 days post-irradiation, and decreased over 30 days. The MN levels in the irradiated fibroblasts, however, remained significantly elevated at all time points relative to unirradiated control cells (Khan et al. 1995). Other in vitro studies have shown the presence of CAs within 13 - 82 hours post-irradiation (Nagasawa et al. 1990; Deshpande et al. 1996; Yamada et al. 2002; Stevens et al. 2014). It was noted in one study that the number or sister chromatid exchanges per cell were significantly higher than non-irradiated control cells at 72 hr post-irradiation, but these levels did not change appreciably at 74, 76, 78 or 82 hours post-irradiation (Deshpande et al. 1996).
In comparison to the time between radiation exposure and CA detection, there is a much longer gap between radiation exposure and the incidence of lung cancer. Oncogenic transformations in fibroblasts irradiated with alpha particles or X-rays were present 4 - 8 weeks after radiation exposure (Robertson et al. 1983; Miller et al. 1996). In vivo irradiation of 1 week-, 5 week- and 15 week-old rats by 1 Gy of thoracic X-rays was found to induce lung tumours months to years after the radiation treatment, with the highest risk for lung tumours found in rats that died between 600 and 900 days of age (Yamada et al. 2017). Similarly, French uranium miners exposed to radon and radon progeny for a minimum of two years were diagnosed at least 10 years after the first radon exposure (Tirmarchel et al. 1993).
Furthermore, direct injection of a CA into mice has also been shown to result in cancer several weeks after the CA administration. Injection of tumourigenic A549 cells that harbour a loss of heterozygosity at chromosome 11 resulted in tumour growth 3 weeks after injection (Kuramochi et al. 2001). Similarly, administration of the BCR/ABL translocation resulted in the mouse equivalent of chronic myelogenous leukemia by 21 - 31 days post-injection (Pear et al. 1998).
Known modulating factors
Some studies have documented modulating factors that affect CAs in lung cancer, including age, ethnicity (Lloyd et al. 2013), smoking (Feder et al. 1998; Paik et al. 2012; Lloyd et al. 2013; Minina et al. 2017), sex (Feder et al. 1998), and genotype (Kim et al. 2012; Minina et al. 2017). In NSCLC patients, ALK and EML4 rearrangements have reportedly been influenced by confounding variables such as age (Shaw et al. 2009; Wong et al. 2009; Sasaki et al. 2010), sex (Shaw et al. 2009), and smoking history (Koivunen et al. 2008; Shaw et al. 2009; Wong et al. 2009; Sasaki et al. 2010).
Known Feedforward/Feedback loops influencing this KER
Domain of Applicability
The domain of applicability applies to mammals such as mice, rats, hamsters and humans.
Al-Zoughool M, Krewski D. 2009. Health effects of radon: A review of the literature. Int J Radiat Biol. 85(1):57–69. doi:10.1080/09553000802635054.
Albertson DG, Collins C, Mccormick F, Gray JW. 2003. Chromosome aberrations in solid tumors. Nature Genetics. 34(4):369-76. doi:10.1038/ng1215.
Balsara BR, Testa JR, Siegfried JM. 1997. Advances in Brief Comparative Genomic Hybridization Overrepresentation Non-Small Cell Lung Carcinomas ’ Analysis Detects Frequent , Often High-Level , of DNA Sequences at 3q , Sp , 7p , and 8q in Human. Cancer Research. 57(11):2116-20.
Bartova E, Kozubek S, Kozubek M, Jirsova P, Lukasova E, Skalnikova M, Buchnickova K. 2000. The influence of the cell cycle , differentiation and irradiation on the nuclear location of the abl , bcr and c - myc genes in human leukemic cells. Leukemia Research. 24(3):233-41.doi: 10.1016/S0145-2126(99)00174-5.
Bjorkqvist A, Husgafvel-pursiainen K, Anttila S, Karjalainen A, Tammilehto L, Mattson K, Vainio H, Knuutila S. 1998. DNA Gains in 3q Occur Frequently in Squamous Cell Carcinoma of the Lung , But Not in Adenocarcinoma. Genes Chromosomes and Cancer. 22(1):79-82. 10.1002/(SICI)1098-2264(199805)22:13.3.CO;2-6.
Boffetta P, Hel O Van Der, Norppa H, Fabianova E, Fucic A, Gundy S, Lazutka J, Cebulska-wasilewska A, Puskailerova D, Znaor A, et al. 2007. Original Contribution Chromosomal Aberrations and Cancer Risk : Results of a Cohort Study from Central Europe. American Journal of Epidemiology.165(1):36–43. doi:10.1093/aje/kwj367.
Bonassi S, Hagmar L, Stro U, Montagud AH, Tinnerberg H, Forni A, Wanders S, Wilhardt P, Hansteen I, Knudsen LE, et al. 2000. Chromosomal Aberrations in Lymphocytes Predict Human Cancer Independently of Exposure to Carcinogens 1. Cancer Research 60(6):1619–1625.
Bonassi S, Norppa H, Ceppi M, Vermeulen R, Znaor A, Fabianova E, Gundy S, Hansteen I. 2008. Chromosomal aberration frequency in lymphocytes predicts the risk of cancer : results from a pooled cohort study of 22 358 subjects in 11 countries. 29(6):1178–1183. doi:10.1093/carcin/bgn075.
Brooks AAL, Miick R, Buschbom RL, Murphy MK, Khan MA, Brooks AL, Miick R, Buschbom RL, Murphy MK, Khan MA. 1995. The Role of Dose Rate in the Induction of Micronuclei in Deep-Lung Fibroblasts In Vivo after Exposure to Cobalt-60 Gamma Rays The Role of Dose Rate in the Induction of Micronuclei in Deep-L Fibroblasts In Vivo after Exposure to Cobalt-60 Gamma Ray. Radiation Research. 144(1):114-8. doi:10.2307/3579244.
Danesi R, Braud FDE, Fogli S, Pas TMDE, Paolo ADI, Curigliano G, Tacca MDEL. 2003. Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer. 55(1):57–103. doi:10.1124/pr.188.8.131.52.
Dang TP, Eichenberger S, Gonzalez A, Olson S, Carbone DP. 2003. Constitutive activation of Notch3 inhibits terminal epithelial differentiation in lungs of transgenic mice. :1988–1997. doi:10.1038/sj.onc.1206230.
Dang TP, Gazdar AF, Virmani AK, Hande KR, Minna D, Roberts JR, Carbone P. 2000. Chromosome 19 Translo- cation, Overexpression of Notch3, and Human Lung Cancer. JNCI Journal of the National Cancer Institute. 92(16):1355–1357. doi: 10.1093/jnci/92.16.1355.
Deshpande AA, Goodwin EH, Bailey SM, Marrone BL, Lehnert BE, Mar N, Deshpande A, Goodwin EH, Bailey SM, Marrone BL, et al. 1996. Alpha-Particle-Induced Sister Chromatid Exchange in Normal Human Lung Fibroblasts : Evidence for an Extranuclear Target Alpha-Particle-Induced Sister Chromatid Exchange in Normal Human Lung Fibroblasts : Evidence for an Extranuclear Target. Radiation Research. 145(3):260-7. doi: 10.2307/3578980.
El-zein RA, Kyle A, Santee J, Yu R. 2017. Identification of Small and Non-Small Cell Lung Cancer Markers in Peripheral Blood Using Cytokinesis-Blocked Micronucleus and Spectral Karyotyping Assays. 77030:122–131. doi:10.1159/000479809.
El-zein RA, Lopez MS, Jr AMDA, Liu M, Munden RF, Christiani D, Su L, Tejera-alveraz P, Zhai R, Spitz MR, et al. 2014. The Cytokinesis-Blocked Micronucleus Assay as a Strong Predictor of Lung Cancer : Extension of a Lung Cancer Risk Prediction Model. 23(November):2462–2471. doi:10.1158/1055-9965.EPI-14-0462.
Feder M, Siegfried JM, Balshem A, Litwin S, Keller SM, Liu Z, Testa JR. 1998. Clinical Relevance of Chromosome Abnormalities in Non-Small Cell Lung Cancer. Cancer Genetics and Cytogenetics 102(1):25-31. doi: 10.1016/S0165-4608(97)00274-4.
Genetic Alliance. 2010. Understanding Genetics: A District of Columbia Guide for Patients and Health Professionals - PubMed - NCBI. Genet Alliance Monogr Guid. https://www.ncbi.nlm.nih.gov/pubmed/23586106.
Girard L, Zo S, Virmani AK, Gazdar AF, Minna JD. 2000. Genome-wide Allelotyping of Lung Cancer Identifies New Regions of Allelic Loss , Differences between Small Cell Lung Cancer and Non-Small Cell Lung Cancer, and Loci Clustering 1. :4894–4906.
Hagmar L, Stro U, Bonassi S, Hansteen I, Knudsen LE, Lindholm C. 2004. Impact of Types of Lymphocyte Chromosomal Aberrations on Human Cancer Risk : Results from Nordic and Italian Cohorts. Cancer Research. 64(6):2258-63. doi:10.1158/0008-5472.CAN-03-3360.
Hei TK, Piao CQ, Willey JC, Thomas S, Hal EJ, Ny R. 1994. Malignant transformation of human bronchial epithelial cells by radon-simulated or-particles. Carcinogenesis. 15(3):431-437. doi: 10.1093/carcin/15.3.431.
Heng HHQ, Bremer SW, Stevens J, Ye KJ, Miller F, Liu G, Ye CJ. 2006. Cancer Progression by Non-Clonal Chromosome Aberrations. 1435:1424–1435. doi:10.1002/jcb.20964.
Heng HHQ, Stevens JB, Liu GOU, Bremer SW, Ye KJ, Reddy P, Wu GENS, Wang YA, Tainsky MA, Ye CJ, et al. 2006. Stochastic Cancer Progression Driven by Non-Clonal Chromosome Aberrations. 472(February):461–472. doi:10.1002/jcp.
Hung J, Kishimoto Y, Sugio K, Virmani A, Mclntire DD, Minna JD, Gazdar AF. 1995. Allele-Specific Chromosome 3p Deletions Occur at an Early Stage in the Pathogenesis of Lung Carcinoma. JAMA The Journal of the American Medical Association. 273(7):558. doi: 10.1001/jama.1995.03520310056030.
Jostes RF. 1996. Genetic , cytogenetic , and carcinogenic effects of radon : a review. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 340(2-3):125-39. doi: 10.1016/S0165-1110(96)90044-5.
Khan MA, Cross FT, Buschbom RL, Brooks AL. 1995. Inhaled radon-induced genotoxicity in Wistar rat , Syrian hamster , and Chinese hamster deep-lung fibroblasts in vivo. 334:131–137.
Kim HR, Shim HS, Chung J, Lee YJ, Hong YK. 2012. Distinct Clinical Features and Outcomes in Never-Smokers With Nonsmall Cell Lung Cancer Who Harbor EGFR or KRAS Mutations or ALK Rearrangement. :729–739. doi:10.1002/cncr.26311.
Knuutila S, Aalto Y, Autio K, Bjorkqvist A-M, El-Rifai W, Hemmer S, Huhta T, Kettunen E, Kiuru-Kuhlefelt S, Larramendy ML, et al. 1999. DNA Copy Number Losses in Human Neoplasms. American Journal Of Pathology. 155(3):683-94. doi: 10.1016/S0002-9440(10)65166-8.
Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, et al. 2008. Cancer Therapy : Preclinical EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer. 14(13):4275–4284. doi:10.1158/1078-0432.CCR-08-0168.
Kuramochi M, Fukuhara H, Nobukuni T, Kanbe T, Maruyama T, Ghosh HP, Pletcher M, Isomura M, Onizuka M, Kitamura T, et al. 2001. TSLC1 is a tumor-suppressor gene in human non-small- cell lung cancer. Nature Genetics. 27(4):427-30. doi: 10.1038/86934.
Liu B, Morrison CD, Johnson CS, Trump DL, Conroy JC, Wang J, Liu S. 2013. Computational methods for detecting copy number variations in cancer genome using next generation sequencing : principles and challenges. Oncotarget. 4(11). doi:10.18632/oncotarget.153.
Lloyd SM, Lopez M, El-zein R. 2013. Cytokinesis-Blocked Micronucleus Cytome Assay and Spectral Karyotyping as Methods for Identifying Chromosome Damage in a Lung Cancer Case-Control Population. 707(September 2012):694–707. doi:10.1002/gcc.
Mao X, Boyd LK, Yáñez-muñoz RJ, Chaplin T, Xue L, Lin D, Berney DM, Young BD, Lu Y. 2011. Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer. American Journal of Cancer Research. 1(5):604-17.
Massion PP, Carbone DP. 2003. The molecular basis of lung cancer : molecular abnormalities and therapeutic implications. Respiratory research. 4(1):12. doi:10.1186/1465-9921-4-12.
Massion PP, Kuo W, Stokoe D, Olshen AB, Treseler PA, Chin K, Chen C, Polikoff D, Jain AN, Pinkel D, et al. 2002. Advances in Brief Genomic Copy Number Analysis of Non-small Cell Lung Cancer Using Array Comparative Genomic Hybridization : Implications of the Phosphatidylinositol 3-Kinase Pathway 1. Cancer Res. 62(13):3636-40.
Miller RC, Richards M, Brenner DJ, Hall EJ, Jostes R, Hui TE, Brooks AL, Miller RC, Richards M, Brenner DJ, et al. 1996. The Biological Effectiveness of Radon-Progeny Alpha Particles . V . Comparison of Oncogenic Transformation by Accelerator-Produced Monoenergetic Alpha Particles and by Polyenergetic Alpha Particles from Radon Progeny. Radiation Research. 146(1):75-80. doi: 10.2307/3579398.
Minina VI, Soboleva OA, Glushkov AN, Voronina EN, Sokolova EA, Bakanova ML, Savchenko YA, Ryzhkova A V, Titov RA, Druzhinin VG, et al. 2017. and chromosomal aberrations in lung cancer patients. J Cancer Res Clin Oncol. 143(11):2235–2243. doi:10.1007/s00432-017-2486-3.
Mitelman F, Mertens F, Johansson B. 1997. chromosomal rearrangements in.
Monchaux G, Morlier JP, Morin M, Chameaud J. 1994. Carcinogenic and Cocarcinogenic Effects of Radon and Radon Daughters in Rats Masses. Environmental Health Perspectives.102(1):64-73. doi: 10.1289/ehp.9410264.
Mukherjee S, Ma Z, Wheeler S, Sathanoori M, Coldren C, Prescott JL, Kozyr N, Bouzyk M, Correll M, Ho H, et al. 2016. Chromosomal microarray provides enhanced targetable gene aberration detection when paired with next generation sequencing panel in profiling lung and colorectal tumors. 209:119–129. doi:10.1016/j.cancergen.2015.12.011.
Nagasawa H, Little JB, Inkret WC, Carpenter S, Thompson K, Raju MR, Chen DJ, Strniste GF. 1990. Cytogenetic effects of extremely low doses of plutonium-238 alpha-particle irradiation in CHO K-1 cells. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis.244(3):233-8. doi: 10.1016/0165-7992(90)90134-6.
Norppa H, Bonassi S, Hansteen I, Hagmar L, Str U, Knudsen LE, Barale R, Fucic A. 2006. Chromosomal aberrations and SCEs as biomarkers of cancer risk. 600:37–45. doi:10.1016/j.mrfmmm.2006.05.030.
Ohshima K, Hatakeyama K, Nagashima T, Watanabe Y, Kanto K, Doi Y, Ide T, Shimoda Y, Tanabe T, Ohnami Sumiko, et al. 2017. Integrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1,454 solid tumors. Sci Rep. 7(1):641. doi:10.1038/s41598-017-00219-3.
Paik PK, Johnson ML, Angelo SPD, Sima CS, Ang D. 2012. Driver Mutations Determine Survival in Smokers and. doi:10.1002/cncr.27637.
Pear BWS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC, Pendergast AM, Bronson R, Aster JC, Scott ML, et al. 1998. Efficient and Rapid Induction of a Chronic Myelogenous Leukemia-Like Myeloproliferative Disease in Mice Receiving P210 bcr/abl-Transduced Bone Marrow. Blood. 92(10):3780-92.
Petersen I, Bujard M, Petersen S, Goeze A, Schwendel A, Langreck H, Gellert K, Reichel M, Just K, Manoir S, et al. 1997. Advances in Brief Patterns of Chromosomal Imbalances in Adenocarcinoma and Squamous Cell Carcinoma of the Lung ’. Cancer Res. 57(12):2331-5.
Robertson A, Allen J, Laney R, Curnow A. 2013. The cellular and molecular carcinogenic effects of radon exposure: A review. International Journal of Molecular Sciences.14(7):14024-63. doi: 10.3390/ijms140714024.
Robertson JB, Koehler A, George J, Little JB. 1983. Oncogenic Transformation of Mouse BALB / 3T3 Cells by Plutonium-238 Alpha Particles. Radiation Research. 96(2):261-74.doi: 10.2307/3576209.
Roscoe RJ, Steenland K, William E, Beaumont JJ, Waxweiler RJ. 1989. Lung Cancer Mortality Among Nonsmoking Uranium Miners Exposed to Radon Daughters. JAMA The Journal of the American Medical Association. 262(5):629-33. doi: 10.1001/jama.262.5.629.
Sanders HR, Albitar M. 2010. Somatic mutations of signaling genes in non-small-cell lung cancer. Cancer Genet Cytogenet. 203(1):7–15. doi:10.1016/j.cancergencyto.2010.07.134.
Sasaki T, Roding SJ, Chirieac LR, Janne PA. 2010. The Biology and Treatment of EML4-ALK Non-Small Cell Lung Cancer. 46(10):1773–1780. doi:10.1016/j.ejca.2010.04.002.The.
Shaw AT, Yeap BY, Mino-kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, Mcdermott U, et al. 2009. Clinical Features and Outcome of Patients With Non – Small-Cell Lung Cancer Who Harbor EML4-ALK. 27(26):4247–4253. doi:10.1200/JCO.2009.22.6993.
Shlien A, Malkin D. 2009. Copy number variations and cancer. Genome Medicine.1(6):62. doi:10.1186/gm62.
Smerhovsky Z, Landa K, Rössner P, Brabec M, Zudova Z, Hola N, Pokorna Z, Mareckova J, Hurychova D. 2001. Risk of Cancer in an Occupationally Exposed Cohort with Increased Level of Chromosomal Aberrations. Environmental Health Perspectives. 109(1):41-5. doi: 10.1289/ehp.0110941.
Smerhovsky Z, Landa K, Rossner P, Juzova D, Brabec M, Zudova Z, Hola N, Zarska H, Nevsimalova E. 2002. Increased risk of cancer in radon-exposed miners with elevated frequency of chromosomal aberrations. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 514(1-2):165-76. doi: 10.1016/S1383-5718(01)00328-X.
Stevens ADL, Bradley S, Goodhead DT, Hill MA, Stevens DL, Bradley S, Goodhead T, Hill MA. 2014. The Influence of Dose Rate on the Induction of Chromosome Aberrations and Gene Mutation after Exposure of Plateau Phase V79-4 Cells with High-LET Alpha Particles The Influence of Dose Rate on the Induction of Chromosome Aberrations and Gene Mutation after. 182(3):331–337. doi:10.1667/RR13746.1.
Thibervile L, Payne P, Leriche J, Horsman D, Nouvet G, Palcic B, Lam S. 1995. Advances in Brief Evidence of Cumulative Gene Losses with Progression of Premalignant Epithelial Lesions to Carcinoma of the Bronchus ’. Cancer Research. 55(22):5133-9.
Tirmarchel M, Raphalen A, Allin F, Chameaud J, Bredon P. 1993. Mortality of a cohort of French uranium miners exposed to relatively low radon concentrations. British Journal of Cancer. 67(5):1090-7. doi: 10.1038/bjc.1993.200.
To MD, Quigley DA, Mao J, Rosario R Del, Hsu J, Hodgson G. 2011. Progressive Genomic Instability in the FVB / Kras LA2 Mouse Model of Lung Cancer. Molecular Cancer Research. 9(10):1339-45. doi:10.1158/1541-7786.MCR-11-0219.
Trask BJ. 2002. Human cytogenetics: 46 Chromosomes, 46 years and counting. Nature Reviews Genetics.3(10):769-78.doi:10.1038/nrg905.
Vacquier B, Caer S, Rogel A, Feurprier M, Tirmarche M, Luccioni C, Quesne B, Acker A, Laurier D. 2008. Mortality risk in the French cohort of uranium miners : extended follow-up 1946 – 1999. :597–604. doi:10.1136/oem.2007.034959.
Vodenkova S, Polivkova Z, Musak L, Smerhovsky Z, Zoubkova H, Sytarova S, Kavcova E, Halasova E, Vodickova L, Jiraskova K, et al. 2015. Structural chromosomal aberrations as potential risk markers in incident cancer patients. (March):557–563. doi:10.1093/mutage/gev018.
Vogelstein B, Kinzler KW. 2004. OUR TENTH YEAR Cancer genes and the pathways they control. 10(8):789–799. doi:10.1038/nm1087.
Walsh L, Dufey F, Tschense A, Schnelzer M, Grosche B, Kreuzer M. 2010. Radon And The Risk of Cancer Mortality- International Poisson Models For The German Uranium Miners Cohort. (December 2009). doi:10.1097/HP.0b013e3181cd669d.
Weaver DA, Hei TK, Hukku B, DeMuth JP, Crawford EL, McRaven JA, Girgis S, Willey JC. 2000. Localization of tumor suppressor gene candidates by cytogenetic and short tandem repeat analyses in tumorigenic human bronchial epithelial cells Localization of tumor suppressor gene candidates by cytogenetic and short tandem repeat analyses in tumorigeni. (March). doi:10.1093/carcin/21.2.205.
Weaver DA, Hei TK, Hukku B, Mcraven JA, Willey JC. 1997. Cytogenetic and molecular genetic analysis of tumorigenic human bronchial epithelial cells induced by radon alpha particles Cytogenetic and molecular genetic analysis of tumorigenic human bronchial epithelial cells induced by radon alpha particles. Carcinogenesis. 18(6):1251-7
Werner AE, Wang Y, Doetsch PW. 2017. A Single Exposure to Low- or High-LET Radiation Induces Persistent Genomic Damage in Mouse Epithelial Cells In Vitro and in Lung Tissue A Single Exposure to Low- or High-LET Radiation Induces Persistent Genomic Damage in Mouse Epithelial Cells In Vitro an. 188(4):373–380. doi:10.1667/RR14685.1.
Wistuba II, Behrens C, Milchgrub S, Bryant D, Hung J, Minna JD, Gazdar AF. 1999. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene. 18(3):643-50. doi: 10.1038/sj.onc.1202349.
Wong DW, Leung EL, So KK. 2009. The EML4-ALK Fusion Gene Is Involved in Various Histologic Types of Lung Cancers From Nonsmokers With Wild-type EGFR and KRAS. doi:10.1002/cncr.24181.
Wrage M, Ruosaari S, Eijk PP, Kaifi JT, Hollme J, Yekebas EF, Izbicki JR, Brakenhoff RH, Streichert T, Riethdorf S, et al. 2009. Human Cancer Biology Genomic Profiles Associated with Early Micrometastasis in Lung Cancer : Relevance of 4q Deletion. 15(5):1566–1575. doi:10.1158/1078-0432.CCR-08-2188.
Yamada AY, Iwata K, Blyth BJ, Doi K, Yamada Y, Iwata K, Blyth BJ, Doi K, Morioka T, Daino K. 2017. Effect of Age at Exposure on the Incidence of Lung and Mammary Cancer after Thoracic X-Ray Irradiation in Wistar Rats Effect of Age at Exposure on the Incidence of Lung and Mammary Cancer after Thoracic X-Ray Irradiation in Wistar Rats. 187(2):210–220. doi:10.1667/RR14478.1.
Yamada Y, Oghiso Y, Enomoto H, Ishigure N. 2002. Induction Of Micronuclei In A Rat Alveolar Epithelia Cell Line By Alpha Particle Irradiation. 99:219–222.
Zabarovsky ER, Lerman MI, Minna JD. 2002. Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. 1234:6915–6935. doi:10.1038/sj.onc.1205835.
Zhang N, Wang M, Zhang P, Huang T. 2016. Biochimica et Biophysica Acta Classi fi cation of cancers based on copy number variation landscapes. BBA - Gen Subj. 1860(11):2750–2755. doi:10.1016/j.bbagen.2016.06.003.